Profit down 57%, share price up 12%. What's with this ASX 200 healthcare stock today?

It's been a rough six months for this ASX 200 giant.

| More on:
A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Fisher & Paykel share price is up 12% right now, trading at $21.57
  • Its gains come on the back of the company's first-half earnings
  • The company posted a 57% drop in NPAT, a 23% slump in revenue, but upped its interim dividend by 3%

The Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) share price is soaring on Tuesday despite the S&P/ASX 200 Index (ASX: XJO) healthcare stock posting seemingly dire first-half earnings.

Though, its results for the six months ended 30 September are in line with previous forecasts.

The Fisher & Paykel share price opened 5.7% higher at $20.30 this morning before peaking at $21.78 – marking a 13.4% gain.

It has since slumped slightly to trade at $21.57 at the time of writing, 12.34% higher than its previous close.

What's going on with this ASX 200 healthcare stock today?

Here are the highlights from Fisher & Paykel's first-half earnings report. All figures have been converted from New Zealand Dollars at today's exchange rate (NZ$1 to AUD$0.93).

  • $88.85 million of net profit after tax (NPAT) – a 57% drop on that of the prior comparable period (pcp)
  • $639.86 million of operating revenue – marking a 23% drop
  • Basic earnings per share (EPS) fell to around 15 cents
  • 17.5 New Zealand cent interim dividend declared (around 16 Aussie cents) ­– a 3% increase on that of the pcp

The respiratory care device company took a notable hit over the first half of financial year 2023 as it cycled COVID-19-driven demand in the pcp. Looking longer-term, however, its results appear more positive.

While its revenue fell on that of the pcp, it increased 21% on that of the comparable pre-pandemic period.

Fisher & Paykel's hospital operating revenue also slumped 35% to $406.47 million last half, while that of its new applications consumables – products used in non-invasive ventilation, Optiflow nasal high flow, and surgical applications – fell 23%. It was a better story for its homecare segment's operating revenue, which lifted 10%.

The company's research and development expenses accounted for 12% of its revenue, or around $78 million.

What else happened in the first half?

The first half was tough on both Fisher & Paykel's earnings and its share price. The stock slumped 27.5% over the six-month period.

Beyond that, the company struggled with higher freight costs and manufacturing inefficiencies. The latter was hampered by demand fluctuations and higher absenteeism.

On a more positive note, it announced its intent to acquire a 105-hectare site for an additional campus in Karaka, Auckland. It hopes to receive regulatory approval on the purchase next year.

What did management say?

Fisher & Paykel Managing director and CEO Lewis Gradon commented on the news driving the ASX 200 stock higher today, saying:

Consistent with what we signalled in August, first half revenue was down on the prior corresponding period as we lapped significant COVID-19-driven demand. Compared to pre-pandemic levels, this represents solid growth.

Customer stock levels of hospital consumables continued to reflect purchases of considerable amounts during our prior half, in preparation for an Omicron hospitalisation wave which proved less severe than originally anticipated.

While we believe the number of hospitals which continue to be overstocked is declining, ultimately, these stocking dynamics are short term, and the fundamentals of our sales strategy remain the same.

It has been pleasing to see a strong reception for our new Evora Full mask, which we began selling into the United States in April.

What's next?

The ASX 200 healthcare stock has declined to provide full-year guidance today.

It cited uncertainties relating to COVID-19 hospitalisations, the severity of the Northern Hemisphere flu season, a surge in respiratory syncytial virus hospitalisations in some regions, and hospital staffing challenges.

Though, Fisher & Paykel expects its revenue to be higher in the second half. The company is also targeting operating expense growth of around 8% for the full year.

"We remain committed to sustainable, profitable growth," Gradon said, continuing:

Our confidence in the future is unchanged, evidenced by the significant level of investment in new product development, our global sales force, and our infrastructure.

Fisher & Paykel share price underperforms ASX 200 in 2022

The ASX 200 healthcare stock has struggled to keep up with the market this year.

Today's gain included, the Fisher & Paykel share price has fallen 31% year to date. It's also 32% lower than it was this time last year.

For comparison, the ASX 200 has dumped 5% in 2022 and is trading flat over the last 12 months.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Web Travel share price rockets 13% on market leading full-year growth

Investors are sending Web Travel shares soaring today. Here’s why.

Read more »

Happy shopper at a clothes shop.
Earnings Results

Why did Myer shares just rocket 9%?

Investors are piling into Myer shares on Friday. But why?

Read more »

A woman looks up at a plane flying in the sky with arms outstretched as the Flight Centre share price surges
Earnings Results

Up 78% since April, why is the Webjet share price taking off again today?

Webjet shares have soared 78% since 4 April and are lifting off again today. But why?

Read more »

a woman holds her hands to her temples as she sits in front of a computer screen with a concerned look on her face.
Industrials Shares

Guess which ASX 200 stock is crashing 24% on results day

Investors were not impressed with this result. But why?

Read more »

A man in full American NFL playing kit crouches over with his arms across his chest in a defensive stance against a dark background.
Technology Shares

ASX 300 tech stock charges 7% higher to record high on stellar results

This tech stock delivered another impressive result this morning.

Read more »

a group of people sit around a computer in an office environment.
Earnings Results

Guess which ASX 200 tech stock is rocketing 12% on record results

Another half, another record result from this high-quality company.

Read more »

A young man sitting at an outside table uses a card to pay for his online shopping.
Consumer Staples & Discretionary Shares

Why is the Kogan share price crashing 12%?

Profits are down at this ecommerce company during the second half.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Resources Shares

Guess which ASX 200 mining stock is sinking 7% following its quarterly update

Let's see how this miner performed during the third quarter.

Read more »